蔡挺, 中国药科大学教授，工学院院长，博士生导师，教育部青年长江学者，江苏省特聘教授，江苏省杰出青年基金获得者，江苏省双创团队领军人才, 江苏省333工程第二层次人才，南京市有突出贡献中青年专家。现任中国药科大学教育部智能制药工程研究中心副主任。专业研究领域为物理药剂学、工业药剂学、制剂工程学，围绕药物新型剂型设计、稳定性和释放等关键科学问题，开展理论及应用研究。本科毕业于复旦大学,博士毕业于美国弗吉尼亚理工大学化学系，后在美国威斯康辛大学麦迪逊分校药学院从事药剂博士后研究工作。回国工作前就职于美国制药公司,工作期间主导多项复杂制剂研发工作。已在JACS、Angew、Adv Mater等国际知名期刊发表SCI论文100多篇，引用3000多次。作为项目负责人主持国家新药创制重大专项、国家自然科学基金、临港国家实验室新药专项、江苏省前沿技术重大专项等项目等多项国家和10多企业合作课题；获得中国药物制剂大会“青年药剂学奖”，江苏省生物技术协会科技创新奖一等奖和“江苏省归侨侨眷先进个人”等荣誉；目前担任药剂学杂志MolecularPharmaceutics，PharmaceuticalResearch， Journal of Pharmaceutical Sciences，Asian Journal of Pharmaceutical Sciences，Chinese Chemical Letters，《中国药科大学学报》、《药学进展》、《药学学报中英文版》、《中国现代应用药学》编委。目前担任中国晶体协会药物晶体学专委会副主任委员，中国药学会制药工程专委会委员，中国药学会药剂专委会青年委员，江苏省生物技术协会青年专委会主任委员。

课题组围绕药剂学和制剂工程学领域的前沿科学问题，利用先进的理化技术手段，开展理论和应用研究工作。主要研究内容包括:

（1）药物晶型及固态化学研究

（2）难溶性药物制剂研究

（3）缓控释及长效制剂研究

（4）药品质量控制与先进制造

（5）药物新制剂与新技术

（1）临港国家实验室国家新药专项，项目编号：LGL-2613-03，461.6万，主持

（2）江苏省前沿技术研发计划，项目编号：BF2024075，500万，主持

（3）国家自然科学基金面上项目，项目编号：22478439，50万，主持

（4）国家自然科学基金面上项目，项目编号：8227388052万，主持

（5）高端外国专家引进计划，项目编号：G2021146003L，40 万，主持，

（6）江苏省杰出青年基金项目，项目编号：BK20190029, 100万，主持，

（7）国家自然科学基金面上项目，项目编号：81872813，57万，主持，

（8）科技部十三五“重大新药创制”科技重大专项，项目编号：2017ZX09301075, 294.78万

1. Chen, A.; Lai, C.; Xu, W.; He, Z.; Zhai, H.; Rui, X.; Guo, M.; Cai, T.* A cocrystal-based long-acting injectable suspension platform enablestunable drug release, Journal of Controlled Release2026, 394,114898

2. Ji, X.; Zhuang, Z.; Liu,H.; Chen,Q.; Yu, Y.; Bao,Y.; Guo, M.; * Cai, T.*Stabilizing liquid-like drug-rich intermediates by bile salts to suppress phase transformation and promote rapid absorption of cocrystals, Journal of Controlled Release2026, 394, 114919

3. Fu,B.; Lu, X.; Pei, X.; Meng,J.; Yang, Y.; Long, W.; Zhai,H.; Wan,Y.; Guo,M.; Peng,Y.;* Cai, T.* Polymorphism control in crystalline clofazimine enables accelerated clinicaltranslation of NIR-II phototheranosticsActa Pharmaceutica Sinica B2026, 16

4. Chen, A.; Peng, Y.; Chen, Z.; Lu, Y.; Guo, M.;* Cai, T.*Crystal engineering for poorly water-soluble drugs: From design to applicationsActa Pharmaceutica Sinica B2026,16,1848

5. Zeng, Q.; Zhang, Y.; Peng, Y.; Zeng, Q.; Sun, G.; Guo, M.*; Cai, T.*Interpretable machine learning for solvent prediction and mechanistic insights in multi-component crystal screeningChemical Engineering Journal, 2025, 524, 16939

6. Yang, Y.; Long, W.; Pei, X.; Li, S.; Fu, B.; Zhai,H.; Zhang,X.; Wan,Y.; Peng,Y.;*Cai, T.*Atorvastatin-Loaded Mineralized Vaccine Reprograms EndosomalTrafficking to Amplify STING-Driven Cancer Immunotherapy, Angew. Chem. Int. Ed.2025, e202503749

7. Meng, J.; Su, Y.; Zhu, H.; Zhang, J.; Cai, T.*Dynamic Molecular Cocrystals with Alkyl Chain Dependent Thermosalient Phase TransitionsAdvanced Science, 2025, 02502692

8. Fan, F.;Lu, Y.; Xu, S.; Guo, M.; Cai, T.*Impact of Polymers on the Kinetics of the Solid-State PhaseTransition of Piracetam Polymorphs,Molecular Pharmaceutics, 2025, 22, 509

9. Peng, Y.; Yao, X.; Hu, X.; Wu, B.; Pei, X.; Yang, Y.; Dong, Z.; An, Z.;* Huang, W.;* Cai, T.*Edible Ultralong Organic Phosphorescent Excipient forAfterglow Visualizing the Quality of TabletsAdvanced Materials, 2024, 36, 40, 202406618

10. Su,Y.; Li, S.; Li, X.; Zhou, J.; Chauhan,V.P.; Li, M.; Su,Y.H.; Liu, C.M.; Ren, Y.F.; Yin, W.;^* Rimer, J.D.;^*Cai, T.^*Tartronic acid as a Potential Inhibitor ofPathological Calcium Oxalate CrystallizationAdvanced Science,2024,2400642

11. Meng,J.; Su,Y.; Zhu,H.;Cai, T.^*Shape Memory and Self-Healing in a Molecular Crystal with InverseTemperature Symmetry BreakingChemical Science, 202415, 5738

12. Chen,A.; Cai,P.; Peng,Y.; Guo,M.; Su, Y.;*  Cai, T.*The role of alkyl chain length in the melt andsolution crystallization of paliperidone aliphaticProdrugs,IUCrJ, 2024, 11, 23

13. Luo, M.; Chen, A.; Huang, C.; Guo, M.; Cai, T.* Effects of Polymers on Cocrystal Growth in a Drug−DrugCoamorphous System: Relations between Glass-to-Crystal Growthand Surface-Enhanced Crystal Growth, Molecular Pharmaceutics, 2024, 21, 3591

14. Peng, Y.; Lei,Y.; Luo,J.; Hu,X.; Sun,F.; Yang,Y.; Guo,M.;Cai, T.* The inherent AIE feature revealed the drug molecular state in cyclodextrin metal–organic framework for enhanced stability and absorption, Chemical Engineering Journal, 2024, 479, 147654

15. Fan, F.; Xu, S.; Guo, M.; Cai, T.*Effect of organic acids on the solid-state polymorphic phase transformation of piracetam, International Journal of Pharmaceutics2023，647, 123532

16. Xu, J.; Chen, A.; Cai, T.*“Polymorphism of purpurin and low-level detection of the noncentrosymmetric form by second harmonic generationmicroscopy” Journal of Pharmaceutical Sciences,2023, 282-289

17. Chen, J.¹; Guo, M.¹; Fan, R.; Peng, Y.; Cai, T.* Impact of Bile Salt on Solution-mediated Phase Transformation of Pharmaceutical Cocrystals: the Importance of Coformer Release Kinetics.Chemical Engineering Journal, 2022, 435, 134928

18. Peng, Y.; Cong, Y.; Lei, Y.; Sun, F.; Xu, M.; Zhang, J.; Fang, L.; Hong, H.;* and Cai, T.*Transforming Passive into Active: MultimodalPheophytin-Based Carbon Dots Customize Protein Coronato Target Metastatic Breast Cancer Adv. Healthcare Mater.2022, 2102270

19. Su, Y.; Bhunia, S.; Xu, S.; Chen, A.; Reddy C.M.*; Cai, T.* “Structure−Thermomechanical Property Correlation in Polymorphic Molecular Crystals Probed by the Nanoindentation Technique” Chemistry of Materials. 2021 33, 4821−4829

20. Guo,M.; Sun, X.; Chen, J.; Cai, T.*“Pharmaceutical cocrystals: A review of preparations, physicochemical properties andapplications” Acta Pharmaceutica Sinica B2021, 11，2537-2564